RecruitingNCT06405256

Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases

Displacement and Deformation Analysis of Adaptive Radiotherapy Based on MR-Linac for Large Brain Metastases


Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment

20 participants

Start Date

Jan 3, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

This study is an ambispective cohort study to evaluate the displacement and deformation of large brain metastases (BM) treated with magnetic resonance imaging-guided adaptive radiotherapy (MRIgART)


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Age ≥ 18 years; KPS score ≥ 60.
  • pathologically confirmed lung cancer.
  • diagnosed with brain metastases by enhanced MRI.
  • BM volume ≥ 2cm.
  • Anticipated time to survival\>3 months.
  • Treated with Unity MR-linac.
  • Good compliance; Able to stay still in supine position for 45 minutes and above.

Exclusion Criteria4

  • Fail to complete radiotherapy as planned; Anticipated time to survival less than 3 months.
  • Suffer from severe back pain in supine position, unable to receive Unity MR-linac.
  • Suffer from severe claustrophobia.
  • Incomplete pre-Unity image data.

Interventions

RADIATIONmagnetic resonance imaging-guided adaptive radiotherapy

Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)


Locations(1)

Chinese Academy of Medical Science and Peking Union Medical College

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06405256


Related Trials